Intratumoral cancer therapy is a type of cancer treatment in which therapeutic agents are directly injected into the tumor tissue via catheters or implanted devices while avoiding the deterioration of the healthy tissues nearby. This therapy aims to localize & inactivate cancer cells & shrink tumors for improved clinical outcomes for the patient.
Market Insights & Analysis: Global Intratumoral Cancer Therapy Market (2023-28)
The Global Intratumoral Cancer Therapy market is projected to grow at a CAGR of around 11.1% during the forecast period, i.e., 2023-28. The growing prevalence of cancer & rising demand for targeted & personalized medicine for treatment is driving the requirement for this therapy in the market. In addition to this, as the advancement in technology & drug development is transpiring, it has led to the evolution of more precise & effective cancer therapies, which results in the adoption of these therapies by the patients & supports market growth.
Moreover, as the number of cancer patients is rising globally, the need for cancer treatment is enhancing & consumers are becoming more aware of the side effects associated with other cancer therapies, such as chemotherapy & radiation therapy. Therefore, a shift has been observed toward consumer preference for novel cancer treatments, which have fewer side effects & more target effects, driving the demand for this cancer therapy among the end-user in the coming years.
|Study Period||Historical Data: 2018-21|
|Base Year: 2022|
|Forecast Period: 2023-28|
|Regions Covered||North America: US, Canada, Mexico|
|Europe: Germany, The UK, France, Spain, Italy, Rest of Europe|
|Asia-Pacific: China, India, Japan, South Korea, Rest of Asia-Pacific|
|South America: Brazil, Rest of South America|
|Middle East & Africa: Middle East, Africa|
|Key Companies Profiled||Amgen Inc., Sirnaomics, Checkmate Pharmaceuticals, Immunovative Therapies, Idera Pharmaceuticals, Daiichi Sankyo, Philogen, Apexigen, Merck, OncoSec Medical Incorporated, DNAtrix, Istari oncology, Nanobiotix, Exicure, Others|
|Unit Denominations||USD Million/Billion|
Additionally, Intratumoral drug delivery is rapidly growing in the field of R&D, with many companies investing in the advancement of novel drug delivery technologies & bringing new and innovative products to market. This has created a lucrative opportunity for the market for this cancer therapy in the forecast year. For instance, in 2022, Merck struck a USD290 million deal with Orion to develop a novel prostate cancer drug.
Moreover, many biotechnology companies are doing mergers & acquisitions to expand, diversify, and strengthen their product portfolio in cancer therapy. For instance, in 2022, Regeneron acquired Checkmate Pharmaceutical, a clinical-stage biopharmaceutical company, & its investigational immune activator for potential use in multiple Tumor Types.
Furthermore, various companies such as OncoSec Medical Incorporated & Intensity Therapeutics are working on developing therapies to treat several cancer diseases like prostrate, breast, etc., which are in the final phases & have the potential to be effective in the treatment in the future, hence augmenting the revenue of the biopharmaceutical company, as well as is predicted to create a potential opportunity for the market growth in the forthcoming period.
Key Driver: Soaring Number of Cancer Cases Driving the Demand for the Therapy
Globally, since the historical period, a high spike in the number of cancer patients has been observed because of the rise in cancer-causing pollutants in the atmosphere, coupled with enhanced penetration of natural UV radiation. The continuous elevation in the range of cancer patients emphasizes the need for accurate & convenient diagnostic systems for the early detection of cancer & hence impacting the demand scale of this cancer therapy. Moreover, fewer side effects, early prognosis, therapy monitoring, etc., are some of the most prominent factors that have further uplifted the adoption of the therapy over conventional ones.
Additionally, the usage of this cancer therapy has also enhanced the treatment procedure for cancer patients, especially for lung & prostate cancer, in which specific target drugs are used for the treatment. Hence, the improved investments by government organizations & pharmaceutical companies to escalate the R&D of new cancer treatments are anticipated to augment the growth of the market during the forecast period.
Possible Restraint: High Cost & Lack of Medical Reimbursement Policies to Hamper the Market Growth
With the prevailing cancer cases in the world, rigorous development has been observed in various novel cancer treatment therapies, such as intratumoral cancer therapy. However, the treatment of these therapies is expensive & is not covered under the insurance policy by many insurance companies as it is a very new & emerging therapy in the market. Therefore, owing to the adjoining concerns, the consumer prefers to adopt known conventional therapies, like biopsies, imaging, mammography, and others, for treatment rather than intratumoral cancer therapy. As a consequence, the market demand for this cancer therapy is presumed to be limited or hindered over time.
Growth Opportunity: Development of Personalized Medicine to Create a Positive Market Outlook
Personalized medicines are treatments that are customized according to a patient's unique genetic, environmental, and lifestyle characteristics to deliver targeted & customized therapies. The rising understanding of the genetic & molecular basis of diseases would significantly support the development of intratumoral personalized cancer therapies in biopharmaceutical companies as it requires the study of patients’ genetic profiles.
Furthermore, the consumers growing awareness of personalized medicines' superior efficacy compared to conventional therapy is expected to drive demand in the coming years. As a result, the evolution of personalized cancer treatment is projected to promote market growth, as it would be needed to deliver targeted therapies based on a patient's cancer type & stage, which is likely to supplement its adoption & use during the forecast period.
Key Trend: Rising Usage of CRISPR-Cas9 Technology
The gradual increase in the utilization of the CRISPR-Cas9 genome, which is an editing tool by researchers & scientists for gene editing, utilized in the development of Intratumoral cancer therapy, is emerging as a major market trend due to its qualitative features. The potential of CRISPR-Cas9 to precisely edit the DNA of cancer cells makes it a promising approach for developing new & effective cancer treatments for patients. Therefore, pharmaceutical companies are adopting this technology for better results in therapy, resulting in the high adoption of this cancer therapy in the forecast years.
Based on the Type:
Above all, Monoclonal Antibodies (mAbs) are depicting significant growth in cancer treatment therapy during the historical years, owing to their ability to target cancer cells with high specificity, potentially reducing off-target effects, and efficacy. This has resulted in the adoption of monoclonal antibodies by Intratumoral therapy (IT) developing companies to produce an effective treatment. Due to this, the potency of this therapy has expanded, which would make this cancer therapy more popular among patients. Hence, the use of mAbs in combination with other Intratumoral therapies, such as chemotherapy or radiation therapy, to develop effective cancer treatment would push its market growth in the forecast years.
Based on the Application:
Above all, Melanoma cancer accounts for the potential share in the market, owing to its more promising treatment results than standard treatments like chemotherapy & radiation therapy. Moreover, Intratumoral cancer therapy is a very efficient therapy for melanoma cancer, as it is localized to the target organ of the body & has a high mutation rate, which results in the development of new target therapies for the treatment. Therefore, due to the unique immunogenic properties, biopharmaceutical companies are working towards a better cure for melanoma cancer, hence enhancing the market in the forthcoming years.
Geographically, the market expands across:
Above all, North America is estimated to have a considerable share of the market owing to the increased presence of cancer therapy and the growing prevalence of cancer in the US. According to the American Cancer Society, around 1.9 million cases of cancer were diagnosed in 2022 in the US. Additionally, the presence of various biotechnology and medical device firms is likely to maintain its lead during the forecast period due to increased spending on research & development initiatives and widespread use of technology in the country.
For instance, in 2023, the US government announced a total budget of USD7.8 billion to the National Cancer Institute (NCI) for cancer research to support, dedicated cancer research activities at the National Cancer Institute. The government and private organization investment to expand the research and development of this therapy for the treatment of cancer in the country is driving the growth of the Intratumoral Cancer Therapy Market.
Recent Developments by the Leading Companies
Do You Require Further Assistance?
Frequently Asked Questions
A. The CAGR of the Intratumoral Cancer Therapy Market is predicted to be around 11.1% during 2023-28
A. Rising number of cancer patient globally is expected to drive the Intratumoral Cancer Therapy Market during 2023-28
A. The top players in the Intratumoral Cancer Therapy Market are Amgen INc., Sirnaomics, Checkmate Pharmaceuticals, Immunovative Therapies, Idera Pharmaceuticals, Daiichi Sankyo, Philogen, Apexigen, Merck, OncoSec Medical Incorporated, DNAtrix, Istari oncology, Nanobiotix, Exicure
A. Monoclonal antibodies, is the leading type in the Intratumoral Cancer Therapy Market .
A. North America would present growth prospects in the Intratumoral Cancer Therapy Market during 2023-28
A. The rising usage of CRISPR-Cas9 technology is the key trends shaping the growth of the Intratumoral Cancer Therapy Market.
A. The development of personalized medicine is the growth opportunity driving the Intratumoral Cancer Therapy through Market 2028.
A. High cost & lack of medical reimbursement policies is the possible restraint affecting the growth of the Intratumoral Cancer Therapy Market.